- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- RTA 901, RTA 901-Matching Placebo
- Drug
- Lead sponsor
- Reata, a wholly owned subsidiary of Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 75
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Canoga Park, California + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 545
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 614
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 338
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
- Conditions
- Lung Carcinoma
- Interventions
- Varenicline, Placebo, Tobacco Cessation Counseling
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 374
- States / cities
- Fairbanks, Alaska • Kingman, Arizona • Jonesboro, Arkansas + 236 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 838
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more
- Conditions
- Aphasia, Apraxia of Speech, Stroke
- Interventions
- Sound Production Treatment - Blocked, Sound Production Treatment - Random
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Post-traumatic Stress Disorder
- Interventions
- Stellate Ganglion Block, Sham Stellate Ganglion Block
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Long Beach, California • Tampa, Florida • Minneapolis, Minnesota + 3 more
- Conditions
- Systemic Lupus Erythematosus, Antiphospholipid Syndrome
- Interventions
- Not listed
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2027
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Baltimore, Maryland • New York, New York + 2 more
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, flutamide, ketoconazole, paclitaxel, releasing hormone agonist therapy, vinblastine sulfate
- Drug
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 63 more
- Conditions
- Contraception
- Interventions
- Relugolix Combination Therapy
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 109
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more
- Conditions
- Chronic Renal Insufficiency, Diabetes Mellitus
- Interventions
- Sodium bicarbonate, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Multiple Sclerosis
- Interventions
- Lipoic acid, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Crohn's Disease
- Interventions
- placebo for risankizumab IV, risankizumab SC, risankizumab IV
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 114
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more
- Conditions
- Healthy Volunteers Sickle Cell Disease, Thalassemia
- Interventions
- Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 76
- States / cities
- Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- temozolomide
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 106
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
- Conditions
- Lymphoma
- Interventions
- rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 60 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2006
- U.S. locations
- 91
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
- Conditions
- COVID-19, SARS-CoV-2 Infection
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 479 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- West Haven, Connecticut • Ann Arbor, Michigan • Durham, North Carolina + 3 more
- Conditions
- Influenza
- Interventions
- CD388 Injection, Placebo
- Combination Product
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 5,071 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 56
- States / cities
- Anniston, Alabama • Cullman, Alabama • Tempe, Arizona + 51 more
- Conditions
- Healthy Participants
- Interventions
- TBP-PI-HBr
- Drug
- Lead sponsor
- Spero Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Vericiguat, Placebo
- Drug
- Lead sponsor
- Josef Stehlik
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes
- Interventions
- PF-08653944, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 55
- States / cities
- Anaheim, California • Canoga Park, California • Cerritos, California + 45 more
- Conditions
- Peripheral Artery Disease (D058729), Oxidative Stress (D018384), Inflammation (D007249)
- Interventions
- PB125, Placebo, Exercise Rehabilitation
- Dietary Supplement · Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Lung Cancer
- Interventions
- cisplatin, vinorelbine ditartrate
- Drug
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2009
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 87 more